secwatch / observer
8-K filed April 18, 2025, 7:59 PM ET ticker LNAI CIK 0001527728
regulatory confidence high sentiment negative materiality 0.65

Lunai Bioworks Inc. (LNAI): Nasdaq/NYSE listing notice — Renovaro receives Nasdaq deficiency notice for low bid price; 180-day cure period

Lunai Bioworks Inc.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Lunai Bioworks Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange
nasdaq
Notice
deficiency notice
Deficiency
minimum bid price
Rules
5550(a)(2), 5810(c)(3)(A)
Exact text from the filing
April 14, 2025, Renovaro Inc. (the “ Company ”) received a deficiency notice from The Nasdaq Stock Market (“ Nasdaq ”) informing the Company that its common stock, par value $0.0001 per share (the “ Common Stock ”), fails to comply with the $1 minimum bid price required for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) based upon the closing bid price of the Common Stock for the 30 consecutive business days prior to the date of the notice from Nasdaq. Nasdaq’s notice has no immediate effect on the listing of the Common Stock on The Nasdaq Capital Market an
View on SEC.gov

93 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Lunai Bioworks Inc. filing history →

Source: SEC EDGAR
accession 0001731122-25-000592
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.